Compare McKesson Corporation (MCK) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Invesco Preferred ETF — how do they compare? McKesson Corporation trades at $824.42 (market cap $97.35B), while Invesco Preferred ETF trades at $10.8. The key difference: McKesson Corporation pays a 0.39% dividend while Invesco Preferred ETF pays none, and McKesson Corporation is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| MCK | PGX | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | — |
52-Week High | $995.69 | $11.87 |
52-Week Low | $659.01 | $10.81 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
PGX trades at $10.81, down 0.46% on the day, with a bearish technical outlook from moving averages and neutral oscillators. The stock shows uniform support and resistance at $11. Recent corporate actions include upcoming dividends of $0.06 and $0.05 scheduled for July and June 2026, respectively. Financial ratios such as P/E, P/S, and ROE are not provided, limiting fundamental assessment.
The outlook for PGX is cautious due to bearish technical signals and negative media sentiment highlighting poor returns and limited downside protection. Investment opportunities may arise from dividend income, but risks include market volatility and structural subordination issues. Investors should weigh the income potential against significant downside risks in volatile conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
